entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.
Company profile
Ticker
TRDA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CycloPorters, Inc.
SEC CIK
Corporate docs
Subsidiaries
Entrada Securities Corporation ...
IRS number
813983399
TRDA stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
S-8
Registration of securities for employees
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
13 Mar 24
8-K
Departure of Directors or Certain Officers
3 Jan 24
UPLOAD
Letter from SEC
20 Dec 23
8-K
Departure of Directors or Certain Officers
6 Dec 23
CORRESP
Correspondence with SEC
6 Dec 23
8-K
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
22 Nov 23
UPLOAD
Letter from SEC
21 Nov 23
Latest ownership filings
144
Notice of proposed sale of securities
25 Apr 24
144
Notice of proposed sale of securities
24 Apr 24
144
Notice of proposed sale of securities
23 Apr 24
144
Notice of proposed sale of securities
19 Apr 24
144
Notice of proposed sale of securities
18 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
144
Notice of proposed sale of securities
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 55.83 mm | 55.83 mm | 55.83 mm | 55.83 mm | 55.83 mm | 55.83 mm |
Cash burn (monthly) | 9.29 mm | 119.08 k | (no burn) | 2.80 mm | 8.16 mm | (no burn) |
Cash used (since last report) | 63.86 mm | 818.80 k | n/a | 19.28 mm | 56.13 mm | n/a |
Cash remaining | -8.02 mm | 55.01 mm | n/a | 36.55 mm | -302.26 k | n/a |
Runway (months of cash) | -0.9 | 462.0 | n/a | 13.0 | -0.0 | n/a |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 17 |
Closed positions | 12 |
Increased positions | 18 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 345.32 bn |
Total shares | 35.79 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 4.87 mm | $73.67 bn |
MPM Asset Management | 4.43 mm | $67.01 bn |
5AM Venture Management | 4.41 mm | $66.74 bn |
5AM Ventures V | 3.28 mm | $83.47 mm |
T. Rowe Price | 2.94 mm | $44.49 mm |
Roche Finance | 2.81 mm | $48.17 mm |
MPM BioVentures 2014 | 2.21 mm | $56.38 mm |
MRL Ventures Fund | 1.74 mm | $29.79 mm |
BLK Blackrock | 1.41 mm | $21.28 bn |
Redmile | 1.31 mm | $19.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 13.573 | 2,600 | 35.29 k | 62,936 |
28 Mar 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 13.7526 | 1,512 | 20.79 k | 60,336 |
26 Mar 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 13.6397 | 2,750 | 37.51 k | 58,824 |
25 Mar 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 13.356 | 3,180 | 42.47 k | 56,074 |
22 Mar 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 13.759 | 3,118 | 42.90 k | 52,894 |
21 Mar 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 13.2353 | 704 | 9.32 k | 49,776 |
20 Mar 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 12.6604 | 1,128 | 14.28 k | 49,072 |
19 Mar 24 | Peter S Kim | Common Stock | Buy | Acquire P | No | No | 12.6633 | 900 | 11.40 k | 47,944 |
15 Mar 24 | Kory James Wentworth | Common Stock | Option exercise | Acquire M | No | No | 2.1 | 9,000 | 18.90 k | 83,170 |
15 Mar 24 | Kory James Wentworth | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.1 | 9,000 | 18.90 k | 43,157 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
11 Apr 24
Insiders Buying America's Car-Mart And 2 Other Stocks
11 Apr 24
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
22 Mar 24
Recap: Entrada Therapeutics Q4 Earnings
13 Mar 24
Entrada Therapeutics Q4 GAAP EPS $(0.29) Misses $(0.17) Estimate, Sales $41.85M Beat $23.69M Estimate
13 Mar 24